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Background: Improvements in antenatal vitamin D status may have maternal-infant health benefits. To inform the
design of prenatal vitamin D3 trials, we conducted a pharmacokinetic study of single-dose vitamin D3
supplementation in women of reproductive age.
Methods: A single oral vitamin D3 dose (70,000 IU) was administered to 34 non-pregnant and 27 pregnant women
(27 to 30 weeks gestation) enrolled in Dhaka, Bangladesh (23°N). The primary pharmacokinetic outcome measure
was the change in serum 25-hydroxyvitamin D concentration over time, estimated using model-independent
pharmacokinetic parameters.
Results: Baseline mean serum 25-hydroxyvitamin D concentration was 54 nmol/L (95% CI 47, 62) in non-pregnant
participants and 39 nmol/L (95% CI 34, 45) in pregnant women. Mean peak rise in serum 25-hydroxyvitamin D
concentration above baseline was similar in non-pregnant and pregnant women (28 nmol/L and 32 nmol/L,
respectively). However, the rate of rise was slightly slower in pregnant women (i.e., lower 25-hydroxyvitamin D on
day 2 and higher 25-hydroxyvitamin D on day 21 versus non-pregnant participants). Overall, average
25-hydroxyvitamin D concentration was 19 nmol/L above baseline during the first month. Supplementation did not
induce hypercalcemia, and there were no supplement-related adverse events.
Conclusions: The response to a single 70,000 IU dose of vitamin D3 was similar in pregnant and non-pregnant
women in Dhaka and consistent with previous studies in non-pregnant adults. These preliminary data support the
further investigation of antenatal vitamin D3 regimens involving doses of ≤70,000 IU in regions where
maternal-infant vitamin D deficiency is common.
Trial registration: ClinicalTrials.gov (NCT00938600)
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Vitamin D is essential for the growth and development of
the human skeleton throughout the life cycle [1]. There is
considerable speculation regarding the potential effects of
vitamin D on both skeletal and extra-skeletal aspects of
reproductive physiology and fetal development, yet it
remains unknown whether there are benefits to improving
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reproduction in any medium, provided the orof severe deficiency [2,3]. Clinical trials employing vitamin
D dose regimens that safely optimize maternal-fetal vitamin
D status will enable testing of these hypotheses [4]. How-
ever, very few studies have rigorously addressed vitamin D
supplementation during pregnancy, and the single-dose
vitamin D3 pregnancy trials published to date have
provided little insight into pharmacokinetics or safety [5,6].
Moreover, there is a near complete absence of pharmaco-
logical data in South Asia, where the vitamin D status of
pregnant women [7] and young infants [8] is poor in spite
of the tropical climate.
The pharmacokinetics of oral vitamin D3 are conventio-
nally described with respect to its effect on the serumd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lite, 25-hydroxyvitamin D ([25(OH)D]), which is a well-
established biomarker of systemic vitamin D status [9].
The present study was conducted to assess changes in
serum [25(OH)D] and calcium following a single oral
vitamin D3 dose (70,000 IU) in non-pregnant women
and pregnant women in the third trimester of pregnancy
in Dhaka, Bangladesh. The aim was to generate preli-
minary pharmacokinetic (PK) and safety data to inform
the design of supplementation regimens for use in




Pregnant and non-pregnant women were enrolled at a
clinic in Dhaka, Bangladesh (24°N) from July 2009 to
February 2010 if they were aged 18 to <35 years, held per-
manent residence in Dhaka at a fixed address, and planned
to stay in Dhaka for at least four months (Figure 1).
Reasons for exclusion were a known medical condition,
self-reported current use of any dietary supplements
containing vitamin D, use of anti-convulsant or anti-
mycobacterial medications, severe anemia (hemoglobin
concentration <70 g/L), or hypertension at enrollment
(systolic blood pressure ≥140 mmHg or diastolic blood
pressure ≥90 mmHg on at least two measurements).
Pregnant women were excluded if they had major risk
factors for preterm delivery (e.g., preterm labor orPregnant women screened in 
Aug-Oct, 2009
N=1115
Pregnant women enrolled 




• Beyond age window, 58 
(5%)
• Beyond gestational age 
window or LMP 
unknown, 978 (89%)
• Lives outside of Dhaka or 
plans to leave, 39 (4%)
• Refusal, 15 (1%)
• Medical/obstetric history, 
10 (1%)
• Already met enrollment 
target, 2 (<1%)
Pregnant women screened in 
Dec 2009 - Feb 2010
N=1285
Exclusions, N=1257 (98%)
• Beyond age window, 78 
(6%)
• Beyond gestational age 
window or LMP unknown, 
1054 (84%)
• Lives outside of Dhaka or 
plans to leave, 59 (5%)
• Refusal, 23 (2%)
• Medical/obstetric history, 4 
(<1%)
• Already met enrollment 
target, 39 (3%)
• Enrolled but did not receive 
loading dose, 14 (1%)
Pregnant women enrolled 
in weekly-dose group in 
February 2010*
N=14
Pregnant women who 
contributed data to 
single-dose analysis
N=27
Figure 1 Flow diagram of participant screening, exclusions, and enroprevious preterm delivery), pregnancy complications or
had previously delivered an infant with a congenital
anomaly or perinatal death. Non-pregnant women were
excluded if they were possibly pregnant (e.g., missed
recent menses) or lactating.
All participants in this study received a dose of vitamin D
(70,000 IU) at baseline. Primary PK analyses involved parti-
cipants who did not receive any additional vitamin D
throughout follow-up (“single-dose group”). However, to
enhance the assessment of 25(OH)D response and safety
during the first week of follow-up, an additional cohort of
participants who continued to receive weekly vitamin D
doses beginning on day 7 (“weekly-dose group”) contribu-
ted biochemical data to the present analysis for the first 7
days after the 70,000 IU dose (i.e., up to the time preceding
their 2nd dose). Findings related to the effect of weekly
dosing will be reported elsewhere. Participants were
enrolled in stages according to a design that enabled in-
terim analyses and the testing of supplementation regimens
in non-pregnant participants prior to their initiation in
pregnant women: non-pregnant participants were enrolled
in the summer (July to September 2009); pregnant women
who received only a single dose were enrolled during the
30th week of gestation in August-September 2009; and,
pregnant participants who received the initial dose followed
by weekly doses were enrolled at 27 to <31 completed
weeks of gestation in February 2010. The study was
reviewed and approved by the Institutional Review Board at
The Johns Hopkins Bloomberg School of Public HealthExclusions, N=436 (96%)
• Beyond age window, 174 
(40%)
• Lactating or possibly 
pregnant, 143 (33%)
• Lives outside of Dhaka or
plans to leave, 83 (19%)
• Refusal, 29 (7%)
• Medical/obstetric history, 
4 (1%)
• Already met enrollment 
target, 3 (<1%)
Non-pregnant women 
screened in July-Aug 2010
N=454
Non-pregnant women 
screened in Aug-Sept 2010
N=408
Exclusions, N=392 (96%)
• Beyond age window, 96 
(25%)
• Lactating or possibly 
pregnant, 185 (47%)
• Lives outside of Dhaka or 
plans to leave, 104 (27%)
• Refusal, 4 (1%)
• Medical/obstetric history, 
2 (<1%)
• Already met enrollment 
target, 1 (<1%)
Non-pregnant women 
enrolled in single-dose 
group in July-Aug 2010
N=18
Non-pregnant women 
enrolled in weekly-dose 
group in Aug-Sept 2010*
N=16
Non-pregnant women 
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Research, Bangladesh (ICDDR,B). All participants gave
signed informed consent prior to participation. The trial
was registered at ClinicalTrials.gov (NCT00938600).
Intervention
Vitamin D3 (cholecalciferol) 70,000 IU (1.75 mg) was
administered directly by study personnel. The dose was
selected to be intermediate between the doses previously
studied in the only two rigorous single-dose vitamin D3
pharmacokinetic studies published at the time our study
was designed (50,000 [10] and 100,000 IU [11]), thus
providing reassurance in terms of probable safety as well
as enabling coherent between-study comparisons. The
vitamin D3 supplement (Vigantol Oil, Merck KGaA,
Germany) was a liquid formulation (20,000 IU D3/mL).
The batch of Vigantol Oil used in the study had a con-
centration of 20,697 IU/mL according to the manufac-
turer’s certificate of analysis (May, 2009). The stability of
the vitamin D3 was established by independent testing of
unused Vigantol Oil at the end of the study (June 2010) in
the laboratory of Dr. Reinhold Vieth [12], which revealed a
concentration of 19,300 IU/mL (96.5% of the labeled
concentration). Participants were advised not to take other
vitamin D-containing supplements during the study period,
but were permitted to take other micronutrient supple-
ments (including calcium). All pregnant participants were
provided standard iron and folic acid supplementation.
Follow-up
Study personnel assessed participants at least weekly. Non-
pregnant participants who received only the single dose
participated in weekly follow-up for 10 weeks; pregnant
women in the single-dose group were assessed at least
weekly until delivery, and then at least three times between
delivery and discharge from the study at one-month post-
partum. Visits involved a checklist of symptoms related to
hypo- and hypercalcemia (decreased appetite, weight loss,
vomiting, fever or chills, constipation, abdominal pain,
excessive thirst, frequent urination, muscle weakness, back,
arm, or leg pain, confusion, or depression), blood pressure










Figure 2 Blood and urine specimen collection schedules. Participants i
(A or B) of specimen collection over a period 70 days. Participants in the “w
schedules (C or D); however, the analysis of single-dose pharmacokinetics o
preceding administration of the 2nd vitamin D dose.Abnormal urinalyses, hypertension, reported severe
symptoms, or persistence of any mild symptomatic com-
plaints (i.e., decreased appetite, weight loss, vomiting, fever
or chills, constipation, abdominal pain, excessive thirst,
frequent urination, muscle weakness, back, arm, or leg
pain, confusion, or depression) for two consecutive visits
prompted referral to the study physician for further eval-
uation. Participants were referred to an antenatal care
physician at the maternity clinic for treatment of urinary
tract infections, hypertension, or other medical problems
that arose. Participants with obstetric complications were
transported to a local tertiary-care hospital with advanced
neonatal care facilities. All costs of medical and obstetric
care were borne by the study.
Specimen collection and biochemical analyses
Participants provided up to six scheduled blood specimens
and at least seven urine samples during the 10-week
follow-up period beginning on the day of supplement
administration (Figure 2). To limit the burden of specimen
collection on each individual, yet still enable robust group-
level pharmacokinetic and safety analyses, participants were
assigned to one of two sampling schedules (A or B) to en-
hance coverage of the follow-up period (Figure 2). During
the first week, specimens were collected at baseline and
then additionally on either day 2 or 4 to monitor for
possible early transient elevations in serum calcium and to
minimize the chance of missing a possible early peak in
[25(OH)D]. In the single-dose only groups, blood collec-
tion thereafter was scheduled predominantly in the first
month because this was when the peak [25(OH)D] [11] and
the highest risk of hypercalcemia were anticipated. In preg-
nant women in the single-dose only group, the specimen
collection schedule was continued in the postpartum period
if delivery occurred prior to 10 weeks from enrollment. In
pregnant participants, venous cord blood samples were
collected immediately following delivery of the placenta.
Serum samples (separated from maternal venous and
umbilical vein blood) and random spot urine specimens
were maintained at +4°C prior to same-day transfer to the
laboratory. Sera were frozen at −20 °C. Aliquots for the 25
(OH)D assay were shipped at ambient temperature fromDay
28 35 42 49 56 63 65 67 70
rine collection Blood collection
n “single-dose only” groups were randomized to one of two schedules
eekly dose” groups were similarly randomized to one of two
nly included those specimens collected up to and including day 7,
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conditions). Total serum [25(OH)D] was measured with
the Diasorin Liaison Total assay in the laboratory of Dr.
Reinhold Vieth (Mount Sinai Hospital, Toronto) according
to a method previously described [13]. This laboratory par-
ticipates in and meets the performance targets of the Inter-
national Vitamin D External Quality Assessment Scheme
[14]. Mean within-run coefficient of variation (CV%) was
7.8% (5.8% for specimens with values < 150 nmol/L) and
mean between-run CV% was 10.5% (9.0% for specimens
<150 nmol/L). Ancillary serum and urine biochemical tests
were performed using the AU640 Olympus Autoanalyzer
(Olympus Corporation, Japan) at ICDDR,B.
The primary pharmacokinetic (PK) outcome measure
was the serum [25(OH)D]; incremental changes from
baseline (Δ[25(OH)D]) were calculated as an individual’s
absolute [25(OH)D] at each visit minus her baseline [25
(OH)D]. The primary safety-related outcome was mater-
nal albumin-adjusted serum calcium concentration
([Ca]), calculated using a conventional formula: [Ca]+(0.02*
(40-albumin)). The reference range for albumin-adjusted
serum calcium was set at 2.10 – 2.60 mmol/L, the
upper limit of which was a conservative threshold rela-
tive to those used by: the local laboratory in Dhaka
(2.62 mmol/L), the US Institute of Medicine (IOM)
1997 dietary reference intakes (DRIs) for vitamin D
(2.75 mmol/L) [15], and the IOM revised 2011 vitamin
D DRIs (2.63 mmol/L) [1]. An albumin-adjusted serum
calcium concentration >2.60 mmol/L prompted a repeat
measurement on a new specimen as soon as possible.
Confirmed hypercalcemia was a priori defined as
albumin-adjusted serum calcium concentration > 2.60
mmol/L on both specimens, since hypercalcemia caused
by vitamin D intoxication would not be expected to
resolve within a few days without intervention.
The urinary calcium:creatinine ratio (ca:cr) was expressed
as mmol Ca/mmol Cr, and 1.0 was considered the nominal
upper limit of the reference range [16]. Any episode of
urinary ca:cr>1.0 mmol/mmol prompted a repeat urine ca:
cr measurement within one week. In addition, a ca:cr >
0.85 mmol/mmol that was also a 2-fold or greater increase
over the lowest previously observed ratio in the same par-
ticipant prompted repeat urine assessment. Persistent
hypercalciuria was defined as ca:cr > 1.0 mmol/mmol on
two consecutive tests, or on two non-consecutive measure-
ments that occurred in the presence of persistent symp-
toms suggestive of possible hypercalcemia. Persistent
hypercalciuria or persistent ca:cr > 0.85 mmol/mmol
(under the conditions listed above) were indications for
unscheduled measurement of serum calcium.
Statistical analyses
Continuous outcome variables were described by means,
standard deviations (SD), and 95% confidence intervals(95% CI). Non-normally distributed variables (including
[25(OH)D]) were described by geometric means with
95% CI’s, medians and interquartile ranges (IQR), and
were log-transformed for modeling. In the primary PK
analysis, the following model-independent PK para-
meters were estimated for each individual in the single-
dose only groups (N=31): 1) maximum observed [25
(OH)D] (Cmax); 2) maximum observed Δ[25(OH)D]
above baseline (ΔCmax); 3) timing of Cmax in days
(Tmax); and 4) area under the Δ[25(OH)D]-time curve
(AUC), which was interpreted as a global measure of
vitamin D3 bioavailability. Individual participants’ AUCs
were estimated manually by the trapezoidal method, and
negative Δ[25(OH)D] values were zeroed so that the
AUC represented the positive area above baseline. AUC
was estimated for the first month to enable comparisons
to other published PK studies [10,11]. AUC28/35 was cal-
culated for either 0 to 28 days or 0 to 35 days, depen-
ding on the timing of the blood sampling (Figure 2);
similarly, AUC56/70 was calculated for the period 0 to 56
days or 0 to 70 days. An individual’s average Δ[25(OH)
D] during the first 28 days (ΔCavg28) was calculated by
dividing AUC28 by 28; for between-study comparisons,
this measure was expressed per 40,000 IU (1 mg)
vitamin D3 by dividing ΔCavg28 by the dose adminis-
tered (1.75 mg). Cmax, ΔCmax, Tmax, AUC28/35, and
AUC56/70 were summarized within groups by geometric
means and 95% CIs, and then log-transformed for one-
way analyses of variance (ANOVA) to test for differences
between the pregnant and non-pregnant groups. To plot
the longitudinal change in [25(OH)D] over time using
all available data (N=61), mean [25(OH)D] at each visit
were predicted from a linear regression model using a
random intercept for each participant, with each visit
represented by its own fixed indicator variable. Cross-
sectional differences in Δ[25(OH)D] between pregnant
and non-pregnant groups at specific days of follow-up
were compared by ANOVA. Changes in biochemical
([Ca] and Ca:Cr) and clinical outcomes from baseline
were analyzed using generalized estimating equations
(GEE) to account for repeated measures. The association
between cord venous [25(OH)D] and the corresponding
maternal [25(OH)D] closest in time to delivery was
analyzed using Pearson correlation.
The target sample size of at least 12 analyzable partici-
pants per single-dose group was originally justified as
follows: assuming two samples per subject (baseline and
peak), a standard deviation for the ΔCmax of 20 nmol/L
and an intra-subject correlation of 0.6, we anticipated
that at least 12 women in each group would enable the
estimation of the mean ΔCmax with 95% confidence
bounds of ±10 nmol/L. In all analyses, P values less than
0.05 were considered to be statistically significant, with
corrections for multiple comparisons using the Holm
Table 1 Changes in [25(OH)D] following a single dose of 70,000 IU vitamin D3 in non-pregnant and pregnant women
in Dhaka, Bangladesh a
All participants Non-pregnant Pregnant P b
N (all participants) 61 34 27
Baseline [25(OH)D] (N=61)
Mean [95% CI] 47 [42, 52] 54 [47, 62] 39 [34, 45] 0.010
Range 21, 96 27, 96 21, 95
Δ[25(OH)D], Mean [95% CI], nmol/L
Day 2 (N=27) 20 [15,25] 24 [17, 33] 15 [11,22] 0.037
Day 4 (N=27) 23 [18, 30] 24 [17, 34] 23 [16, 32] 0.800
Day 7 (N=29) 26 [21, 33] 25 [18, 34] 28 [20, 40] 0.134
Day 21 (N=14) 25 [18, 35] 21 [14, 33] 32 [20, 51] 0.003
Day 56 (N=12) 16 [11,23] 14 [9,21] 20 [12, 33] 0.101
Participants in single-dose only groups
N (% followed more than 7 days) 31 (51%) 18 (53%) 13 (48%)
# Specimens per participant
Median 6 6 6
Range 3, 6 3, 6 3, 6
Baseline [25(OH)D] (N=31)
Mean [95% CI] 48 [41, 56] 52 [42, 64] 43 [34, 55] 0.224
Range 21, 96 27, 96 21, 95
Tmax, days (N=31)
Mean [95% CI] 11 [7,18] 9 [4,17] 17 [10,29] 0.134
Range 2, 70 2, 70 2, 70
Cmax, nmol/L (N=31)
Mean [95% CI] 85 [77, 93] 87 [75, 101] 82 [72, 92] 0.500
Range 51, 164 51, 164 52, 116
ΔCmax, nmol/L (N=31)
Mean [95% CI] 30 [23, 39] 28 [18, 42] 33 [24, 46] 0.486
Range 2, 87 2, 87 9, 52
Area under the curve, nmol·d/L c
AUC56/70, Mean (N=30) 935 910 969 0.863
[95% CI] [651, 1343] [531, 1559] [563, 1668]
AUC28/35, Mean (N=31) 591 562 632 0.672
[95% CI] [448, 780] [383, 823] [398, 1003]
ΔCavg28/35 per mg dose
d (nmol/L/mg)
[95% CI] 12 [10,15] 12 [8,15] 14 [10,18] 0.370
a. [25(OH)D] summary measures are geometric means with exponentiated 95% confidence intervals, unless otherwise indicated.
b. One-way analysis of variance (ANOVA) test for difference between non-pregnant and pregnant groups.
c. AUC was only estimated using data from participants with follow-up to the end of the interval of interest (i.e., 28/35 days or 56/70 days).
d. Average [25(OH)D] over the first 28 or 35 days, per mg of the single vitamin D3 dose. Arithmetic means and 95% confidence intervals reported because these
estimates had an approximately normal distribution.
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conducted using Stata version 10 and 11 (Stata Corpor-
ation, College Station, Texas).
Results
In the single-dose only groups, follow-up for the full 10
weeks was completed in all non-pregnant (N=18) and preg-
nant (N=13) participants; however, the terminal serum
sample for one non-pregnant participant (at day 56) was
not suitable for analysis. Cord blood specimens were avai-
lable for 12 of 13 pregnant participants in the single-dose
only group. An additional 16 non-pregnant and 14 preg-
nant participants enrolled in weekly-dose groups contribu-
ted at least one [25(OH)D] value on or prior to day 7.
At baseline, pregnant participants had lower average
[25(OH)D] than non-pregnant participants (Table 1);
this was partly attributable to the design of the study,
whereby some pregnant women were enrolled in the
winter and all non-pregnant women were enrolled in the
summer and fall (Table 2). Pregnant participants were
generally younger, more likely to be married, and of a
slightly lower socioeconomic status than non-pregnant
participants (Table 2).Table 2 Personal and household characteristics of participant
Single-dose only group
Non-pregnant Pregnant
# Enrolled 18 13
Month of enrollment
July-August, 2009 18 (100 %) 5 (38 %)
Sept-Oct 2009 0 8 (62 %)
February 2010 0 0
Age (years), Mean (±SD) 23.9 (±3.8) 20.9 (±2.7)
Married 11 (61%) 13 (100%)
Education level attained
None 1 (6%) 2 (15%)
Primary 11 (61%) 7 (54%)
Secondary or higher 6 (33%) 4 (31%)
Husband’s education level
None 2 (18%) 3 (23%)
Primary 4 (36%) 4 (31%)
Secondary or higher 5 (45%) 6 (46%)
Home ownership 6 (33%) 1 (8%)
House constructed from cement, brick or tile b
Floor 18 (100%) 11 (85%)
Walls 16 (89%) 10 (77%)
Roof 6 (33%) 6 (46%)
Height (cm), mean (±SD) 149.7 (±3.7) 150.3 (±3.9)
a. ANOVA for comparisons of continuous variables, Fisher’s exact test for categorical
b. In comparison to tin or natural materials (e.g., earth, bamboo).Pharmacokinetic outcomes
There was substantial inter-individual variation in the shape
and magnitude of 25(OH)D responses to a single oral dose
of 70,000 IU vitamin D3. However, the population-average
pattern consisted of an abrupt increase in [25(OH)D] in the
first week, followed by a peak within the first three weeks,
and then a gradual return to baseline over the ensuing two
months in both non-pregnant and pregnant participants
(Figure 3). The average [25(OH)D] remained marginally
above baseline at ten weeks after supplementation. There
were minor differences between the pregnant and non-
pregnant groups in the average Δ[25(OH)D] throughout
follow-up (Table 1). In particular, [25(OH)D] rose more
rapidly and the peak average occurred earlier in the non-
pregnant group. This was demonstrated by the significantly
greater Δ[25(OH)D] on day 2, the significantly lower
Δ[25(OH)D] on day 21, and the slightly earlier occurrence
of Tmax in non-pregnant vs. pregnant women (Table 1).
Moreover, there was greater variance in the early Δ[25(OH)
D] in non-pregnant vs. pregnant participants (Figure 3).
The highest [25(OH)D] in any non-pregnant participant
was 164 nmol/L, whereas the maximum in any pregnant
participant was 116 nmol/L. On average, pregnant womens at enrollment
All participants
P Non-pregnant Pregnant P a
34 27
<0.001 33 (97%) 5 (19%) <0.001
1 (3%) 8 (30%)
0 14 (52%)
0.022 24.2 (±4.1) 21.6 (±2.9) 0.006
0.025 23 (68%) 27 (100%) 0.001
0.750 3 (9%) 6 (22%) 0.293
21 (62%) 16 (59%)
10 (29%) 5 (19%)
1.000 2 (9%) 4 (15%) 0.786
10 (43%) 13 (48%)
11 (48%) 10 (37%)
0.191 7 (21%) 2 (7%) 0.276
0.168 33 (98%) 22 (81%) 0.079
0.625 30 (88%) 18 (67%) 0.042
0.710 13 (38%) 7 (26%) 0.412























































Figure 3 Serum [25(OH)D] in non-pregnant (A) and pregnant (B) participants following administration of 70,000 IU vitamin D3 at day
0. Predicted mean [25(OH)D] and 95% confidence intervals were estimated in a random-intercept regression model of ln[25(OH)D] as a function
of time.
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rise in [25(OH)D] (i.e., ΔCmax) and AUC were similar in
pregnant and non-pregnant women (Table 1). Overall, the
[25(OH)D] was an average of 19 nmol/L (95% CI, 14 to 25)
higher than baseline during the first month after supple-
mentation, which corresponded to a gain of approximately
12 nmol/L per mg of the vitamin D3 dose (Table 1).
Safety outcomes
The supplement was tasteless and well tolerated and there
were no supplement-related adverse events (Table 3). The
stillbirth and newborn deaths were explained by medical
problems, and there was no evidence that either was relatedto the vitamin D supplementation, given their timing
(i.e., did not occur at peak [25(OH)D]) and the absence of
biochemical evidence of vitamin D toxicity in the mother
(Table 3). Postmortem examinations were not feasible in
the study setting. Two other AEs resolved without compli-
cations and occurred in the absence of evidence of vitamin
D toxicity (Table 3). Pregnancy and birth outcome metrics
were consistent with expectations for the source population
(Table 4).
Changes in average serum calcium concentrations
(Figure 4) and urinary calcium excretion (Figure 5)
occurred during the early phase of [25(OH)D] escalation.
In non-pregnant participants, a transient increase in
Table 3 Individual cases of elevated serum calcium or clinical adverse events among pregnant participants who
received 70,000 IU vitamin D3 a
Event Biochemistry b Action Outcome















day 42 of follow-up.









Event 2.38 0.74 71
Post-event 2.46 0.16 80
Range 2.38 to 2.48 0.05 to 0.74 71 to 116







day 17 of follow-up.











Event 2.26 0.74 85
Post-event 2.29 1.04 75
Range 2.24 to 2.37 0.22 to 1.04 46 to 85








day 28 of follow-up.









Event 2.45 0.18 54









partum; day 70 of
follow-up














Post-event 2.52 – 30
Range 2.3 to 2.61 0.14 to 1.74 47 to 70










35 weeks, 5 days
gestational age.












Event 2.38 0.05 45
Post-event 2.46 0.05 46
Range 2.31 to 2.46 0.02 to 0.57 21 to 52
Cord blood 2.28 – 29
a. Table includes participants with at least one serum albumin-adjusted calcium concentration measurement greater than 2.60 mmol/L or a serious clinical adverse
event at any time during follow-up, among participants in the single-dose only group.
b. All values refer to serum concentrations in maternal venous blood except for the row labeled “cord blood”. “Range” refers to the participant’s range of values
during the entire follow-up period.
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day 4 (Table 5; Figure 4). The corresponding change in un-
adjusted total serum [Ca] was smaller and non-significant,
and the raised adjusted [Ca] coincided with a lower average
serum albumin on day 4 (difference versus baseline,
-1.23 g/L; 95% CI, -2.12 to −0.34). In pregnant participants,
there was an initial increase in albumin-adjusted [Ca]
beginning on day 2 that persisted until nearly the end of
the observation period (Figure 4), but the difference from
baseline was only statistically significant on day 7 (Table 6).
The unadjusted total [Ca] did not vary greatly from baseline
and serum albumin remained relatively stable until the endof the 70-day follow-up, when many of the participants
were post-partum.
There were no episodes of confirmed hypercalcemia
according to the study definition, and no isolated albumin-
adjusted [Ca] values greater than the recent IOM upper
limit of normal of 2.63 mmol/L. One pregnant participant
had a single albumin-adjusted [Ca] = 2.61 mmol/L at one-
week postpartum (70 days after dose administration) corre-
sponding to a normal total [Ca] (2.51 mmol/L; serum albu-
min concentration was 35.8 g/L) that was within the
reference range on repeat testing 4 days later (Table 3;
Figure 6). A further follow-up one week following the first
Table 4 Pregnancy and newborn outcomes for pregnant
participants who received only a single dose of 70,000 IU
vitamin D at enrollment and were followed up to
delivery
N 13
Gestational age at birth, weeks (by LMP) a Mean (±SD) 38.8 (±1.8)
Range 35.7 – 42.0
Preterm, n (%) 2 (15%)
Birth weight b (g)
Mean (±SD) c 2441 (±354)
Range (g) 1890 – 3005
n/N (%) Low Birth Weight 6/12 (50%)
Delivery mode, n/N (%) Cesarean section d 8/13 (62%)
Sex, n (%) female 5 (38%)
Live births e 12/13
Alive at 1 month of age f 11/13
a. In a sample of 113 deliveries at the study site (October 2009 to January
2010) for which there was a recalled first day of last menstrual period, the
mean gestational age at birth was estimated to be 39.7 weeks (±2.2).
b. Only includes the 12 liveborn infants.
c. In a consecutive sample of 362 liveborn infants delivered at the study site
(October 2009 to January 2010), the mean birth weight was 2780 g (±440).
d. In a consecutive sample of 369 deliveries at the study site (October 2009 to
January 2010), there were 199 cesarean deliveries (54%).
e. There was one stillbirth. In a consecutive sample of 369 deliveries at the
study site (October 2009 to January 2010), there were 7 stillbirths (2%).
f. There was one neonatal death at 3 days of age.
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[Ca] of 2.44 mmol/L). This participant also had two non-
consecutive episodes of urinary ca:cr higher than 1.0
mmol/mmol during follow-up (Figure 6). Her serum
biochemical patterns were consistent with the expected
changes in the perinatal period, including a gradual increase
in albumin-adjusted serum [Ca] towards the end of the
antenatal period and a rapid increase in serum albumin in
the post-partum period [18]. Furthermore, there was no
temporal association between the rise in [25(OH)D] and
either the occurrence of isolated peaks in urine ca:cr or the
isolated elevated [Ca] (Figure 6).
None of the participants manifested persistent hypercal-
ciuria according to the study definition, or using a more
conservative threshold of 0.85 mmol/mmol. In non-
pregnant participants, the Ca:Cr increased from baseline
but differences were only statistically significant at day 7
and 14 (Table 5). In pregnant participants, the increases in
average Ca:Cr above baseline were more persistent and
were statistically significant on all days except day 42, 49,
and 70 (Table 6). There was no overall difference in the
average ca:cr between non-pregnant and pregnant partici-
pants (P= 0.857).
Cord blood biochemistry
Among participants who had received a single dose at base-
line and for whom cord blood specimens were collected(N=12), the geometric mean cord serum [25(OH)D] was 50
nmol/L (95% CI, 40 to 62; range, 29 to 80). All cord serum
albumin-adjusted [Ca] were within the normal range. The
cord ln[25(OH)D] was moderately correlated with the ma-
ternal ln[25(OH)D] closest to the time of delivery (Pearson
rho=0.64, P=0.02), and the average ratio of cord:maternal
[25(OH)D] (N=12) was 0.88 (95% CI, 0.76 –1.02).
Discussion
This single-dose oral vitamin D3 pharmacokinetic study
generated novel observations regarding the biochemical
response to vitamin D3 in women of reproductive age in
South Asia. Overall, we found that the average response
was similar to that reported for non-pregnant adults in
other geographic settings. The occurrence of the maximal
mean [25(OH)D] in the first month was consistent with
previous studies of single-dose vitamin D3 (1.25 to 15 mg)
administered to non-pregnant adults in North America,
Europe and Australia [10,11,19-23]. When expressed as a
function of vitamin D3 dose (assuming the rise is linearly
proportional to dose), the mean overall ΔCmax of 30
nmol/L (28 nmol/L in non-pregnant and 33 nmol/L in
pregnant participants) represented an average maximal
rise in [25(OH)D] of ~17 nmol/L per mg D3. This esti-
mate was similar to those of previous studies from which
relevant inferences could be drawn, in which the average
ΔCmax ranged from 12 to 16 nmol/L per mg of vitamin
D3 [10,11,19,20].
We are not aware of previous single-dose vitamin D3
pharmacokinetic studies in pregnancy to which the present
findings can be directly compared. However, there are
emerging data regarding the efficacy and safety of high-
dose continuous regimens in pregnancy; for example, Hollis
et al. reported that 4000 IU/day vitamin D3 initiated in the
2nd trimester yielded an increase in mean [25(OH)D] from
58 nmol/L to 111 nmol/L at delivery among women in
South Carolina, without inducing hypercalcemia or other
observed adverse effects [24]. In comparison, Vieth observed
in non-pregnant adults that 4000 IU/day led to an increase
in mean [25(OH)D] from 38 to 96 nmol/L at steady-state
[16]. Thus, from a pharmacokinetic standpoint, the Hollis
et al. findings are in accord with our conclusion that
pregnancy does not substantially alter the 25(OH)D
response to vitamin D3.
There was substantial inter-individual variability in 25
(OH)D responses. Many participants demonstrated a rapid
rise in [25(OH)D] during the first week, which is similar
to the response to an acute dose of ultraviolet radiation
exposure [25]; but distinct from the more gradual effects of
other forms of exogenous vitamin D intake (e.g., oral D2
ingestion [10]). Several non-pregnant participants demon-
strated peak [25(OH)D] as early as two days after supple-
ment delivery, and there was notably wider variability in










































































Figure 4 Albumin-adjusted serum calcium concentration ([Ca]) in non-pregnant (A) and pregnant participants (B) following
administration of vitamin D3 70,000 IU at day 0. Dashed horizontal lines represent upper and lower bounds of the reference range. Predicted
means and 95% confidence intervals were estimated in a linear regression model using GEE.
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http://www.nutritionj.com/content/11/1/114during the early escalation phase compared to pregnant
participants. It is possible that the greater apparent var-
iability was an artifact due to lower precision of the 25
(OH)D assay at higher [25(OH)D], given the higher ave-
rage [25(OH)D] in non-pregnant women. Higher concen-
trations of vitamin D-binding protein during pregnancy
[[26] may have efficiently buffered the absorbed vitamin
D3 and slowed its transport to the liver where it undergoes
25-hydroxylation [27]].
Vitamin D3 bioavailability (measured by mean AUC and
dose-adjusted ΔCavg28) differed minimally between the
non-pregnant and pregnant groups, and between-group
differences were overshadowed by between-subjectvariability. The overall ΔCavg28 (i.e., estimated average [25
(OH)D] rise from baseline in the first month, expressed per
milligram of vitamin D3) was 12 nmol/L/mg based on an
aggregate analysis of individual empiric AUCs. This result
was the same as the ΔCavg28 of ~12 nmol/L/mg found in
studies of non-pregnant adults using 50,000 IU and
100,000 IU [11]], and similar to an extrapolated estimate of
13 nmol/L/mg based on data reported for a single dose of
300,000 IU in elderly adults [19]. The ΔCavg28 provides a
useful summary measure for between-study comparisons
because most of a single ingested vitamin D3 dose is con-
verted to 25(OH)D within one month [11]. The consistency
































































Figure 5 Calcium:creatinine ratios (Ca:Cr) in spot urine specimens from non-pregnant (A) and pregnant participants (B) following
administration of vitamin D3 70,000 IU at day 0. Predicted means and 95% confidence intervals were estimated in a linear regression model
using GEE, in which log-transformed Ca:Cr was modeled as a function of time.
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http://www.nutritionj.com/content/11/1/114previous studies supports the contention by Heaney et al.
that 25(OH)D bioavailability is proportional to vitamin D3
input across a wide dose range (1.25 to 7.5 mg) [11]. Not-
ably, ΔCavg28 extracted from a study by Cipriani et al. was
somewhat lower (~ 8 nmol/L/mg) [20]. We speculate that
the massive dose administered in that study (600,000 IU)
saturated the hepatic 25-hydroxylase system, resulting in
the engagement of subsidiary vitamin D catabolic pathways
which reduced the 25(OH)D yield.
The single vitamin D3 dose of 70,000 IU did not pro-
voke hypercalcemia or hypercalciuria in non-pregnant or
pregnant participants, and available data indicated thatadverse perinatal events were neither temporally nor
mechanistically linked to vitamin D supplementation.
An isolated serum [Ca] value above the reference range
in one pregnant participant occurred in the early post-
partum period, when albumin-adjusted [Ca] typically
peaks [18]. This was not due to vitamin D toxicity because
her [25(OH)D] at the time was 47 nmol/L and the [Ca]
rapidly and spontaneously normalized. However, it is
important to acknowledge that there were significant
increases in average [Ca] and urine ca:cr. Changes in serum
[Ca] were not reportedly significant in studies by Ilahi [11],
Armas [10], or Romagnoli [19], but Cipriani et al.
Table 5 Serum calcium and urinary calcium:creatinine following single-dose vitamin D3 (70,000 IU) in non-pregnant
participants





















0 34 0.21 0.19 (0.22) 0.04 to
1.55
1




0 – – – – –
4 days 16 2.48 (0.06) 2.42
(0.07) c
2.3 to 2.6 0 – – – – –
2nd to 4th week (days 7 to
27)




0 47 0.34 d 0.36 (0.23) 0.09 to
1.49
3
5th to 8th week (days 28 to
55)




0 53 0.28 0.35 (0.37) 0.01 to
1.12
2
9th to 11th week (days 56 to
76)




0 37 0.24 0.25 (0.26) 0.01 to
0.88
0




0 172 0.26 0.3 (0.3) 0.01 to
1.55
6
a. Number of specimens (there may have been multiple specimens for a single participant during a given follow-up period).
b. Geometric means.
c. Mean at day 4 was higher than baseline (+0.05; 95% CI, 0.03 to 0.07) and this remained statistically significant after correction for multiples testing.
d. Means at days 7 and 14 were significantly higher than baseline, after correction for multiple testing.
e. Mean at day 70 was significantly lower than baseline, after correction for multiple testing.
Table 6 Serum calcium and urinary calcium:creatinine following single-dose vitamin D3 (70,000 IU) in pregnant
participants
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0.69
0




0 – – – – –




0 – – – – –
2nd to 4th week (days 7 to
27)




0 33 0.33 d 0.31 (0.31) 0.06 to
1.05
3
5th to 8th week (days 28 to
55)




0 35 0.31d 0.41 (0.31) 0.05 to
1.48
4
9th to 11th week (days 56 to
76)




1 28 0.33 d 0.36 (0.36) 0 to 1.74 2




1 123 0.24 0.33 (0.36) 0 to 1.74 9








0 – – – – –
a. Number of specimens (there may have been multiple specimens from a single participant during a given follow-up period).
b. Geometric means.
c. Mean at day 7 was higher than baseline (+0.05; 95% CI, 0.01 to 0.08), which remained statistically significant after correcting for multiple testing.
d. Means at days 7, 14, 21, 28, 35, 56, and 63 were significantly higher than baseline, after correcting for multiple testing.
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– – Upper limits of reference range ([Ca], 2.6 mmol/L; ca:cr, 1.0 mmol/mmol)
Figure 6 Serum and urine biochemistry in a pregnant participant with two episodes of urine ca:cr > 1.0 mmol/mmol and one episode
of serum albumin-adjusted [Ca] > 2.60 mmol/L. Vertical line indicates timing of delivery at 39 weeks gestation.
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http://www.nutritionj.com/content/11/1/114demonstrated that the administration of a single dose
of 600,000 IU to healthy young adults caused an in-
crease in serum [Ca] at 3 days, coinciding with peak
serum concentrations of both 25(OH)D and the active
metabolite, 1,25-dihydroxyvitamin D (1,25(OH)2D) [20].
Therefore, upward deflections in the serum and urine bio-
markers of calcium homeostasis signaled a need to be cau-
tious about the transient effects of large sudden influxes
of vitamin D, and the risk of dose-dependent toxicity.
There were several limitations of this study. First, al-
though we were able to closely monitor the participants
to gain preliminary PK and safety data in this popula-
tion, the small sample size limited the precision of effect
estimates and comparisons of non-pregnant and preg-
nant participants. Moreover, we did not have adequate
power to adjust for differences in the baseline character-
istics of the pregnant and non-pregnant groups,
although we did not expect minor variations in age or
socioeconomic status to influence biochemical responses.
Second, the low number of scheduled blood specimens
collected from each individual compromised the precision
of the estimates of individual-level PK parameters. The
number was limited by available funds and the expected
acceptability of the procedure by participants based on pre-
study consultation with local community members. Third,
the fixed timing of specimen collection had the disad-
vantage of leaving gaps in the [25(OH)D]-time curve whereno data were available. Fourth, the study lacked an
unsupplemented control group. The analysis was chal-
lenged by the substantial inter-individual variability in
responses to supplementation, which was expected
based on previous reports [28]. Several participants
had fluctuating [25(OH)D], without a single clear peak
and decline, and some manifested seemingly para-
doxical responses, with initial declines in [25(OH)D]
after D3 ingestion. These erratic patterns could not
easily be explained on the basis of known vitamin D
pharmacokinetics, but were most likely attributable to
small-sample artifacts, biological variability in the
absorption and metabolism of vitamin D, and inherent
imprecision in the laboratory assessment of [25(OH)
D]. Nonetheless, the data yielded coherent population-
averaged interpretations that were consistent with
published data from non-pregnant adults in other settings.
Conclusions
Comparisons of pregnant (third-trimester) to non-pregnant
participants, as well as comparisons to previously published
PK studies in non-pregnant adults, suggested that the
effects of pregnancy on the 25(OH)D response to vitamin
D3 were relatively minor and did not substantially impact
overall bioavailability. Likewise, we did not document any
notable pregnancy-related hypersensitivity to a vitamin D
dose of 70,000 IU in terms of its effects on calcium
Roth et al. Nutrition Journal 2012, 11:114 Page 14 of 15
http://www.nutritionj.com/content/11/1/114homeostasis. However, the unpredictability of the 25(OH)D
response at the individual level, previous reports of adverse
effects of large single doses [23], and the theoretical disad-
vantages of excessive fluctuations in vitamin D status [29]
suggest that the use of large single or infrequent intermit-
tent doses of vitamin D3 may be physiologically disadvanta-
geous despite its practical appeal. Therefore, these data
principally support the further investigation of single doses
equal to or less than 70,000 IU in the context of intermit-
tent (e.g., weekly or biweekly) antenatal dosing regimens.
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